Abstract 204P
Background
Although neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for esophageal cancer patients, most patients are unable to achieve pathological complete response with neoadjuvant therapy, resulting in poor outcomes. The aim of this study is to develop a method for selecting patients who can achieve pathological complete response through pre-neoadjuvant therapy chest-enhanced CT scans.
Methods
Two hundreds and one patients with esophageal cancer were enrolled and divided into a training set and a testing set in a 7:3 ratio. Radiomics features of intra-tumoral and peritumoral images were extracted from preoperative chest-enhanced CT scans of these patients. The features were dimensionally reduced in two steps. The selected intra-tumoral and peritumoral features, including marginal (with a distance of 0-3mm from the tumor) and adjacent (with a distance of 3-6mm from the tumor) ROI, were used to build models with four machine learning classifiers, including Support Vector Machine, XG-Boost, Random Forest and Naive Bayes. Models with satisfied accuracy and stability levels were considered to perform well. Finally, the performance of these well-performing models on the testing set was displayed using ROC curves.
Results
Among the 16 models, the best-performing models were the integrated (intra-tumoral and peritumoral features)-XGBoost and integrated-random forest models, which had average ROC AUCs of 0.906 and 0.918, respectively, with relative standard deviations (RSDs) of 6.26 and 6.89 in the training set. In the testing set, the AUCs were 0.845 and 0.871, respectively. There was no significant difference in the ROC curves between the two models. Table: 204P
The performance of the selected models on the testing set
Model | AUC (95% CI) | Specificity | Sensitivity |
Integrated-XGBoost | 0.845 (0.764, 0.928) | 0.864 | 0.777 |
Original-XGBoost | 0.759 (0.660, 0.857) | 0.900 | 0.592 |
Integrated-Random Forest | 0.871 (0.796, 0.946) | 0.682 | 0.933 |
Original-Random Forest | 0.795 (0.703, 0.887) | 0.825 | 0.673 |
Adjacent-Random Forest | 0.769 (0.671, 0.868) | 0.886 | 0.533 |
Integrated-Support Vector Machine | 0.719 (0.613, 0.825) | 0.795 | 0.622 |
Conclusions
The addition of peritumoral radiomics features to the radiomics analysis may improve the predictive performance of pathological response for esophageal cancer patients to neoadjuvant chemoradiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract